» Articles » PMID: 23532511

Cross-validation for Nonlinear Mixed Effects Models

Overview
Publisher Springer
Specialty Pharmacology
Date 2013 Mar 28
PMID 23532511
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Cross-validation is frequently used for model selection in a variety of applications. However, it is difficult to apply cross-validation to mixed effects models (including nonlinear mixed effects models or NLME models) due to the fact that cross-validation requires "out-of-sample" predictions of the outcome variable, which cannot be easily calculated when random effects are present. We describe two novel variants of cross-validation that can be applied to NLME models. One variant, where out-of-sample predictions are based on post hoc estimates of the random effects, can be used to select the overall structural model. Another variant, where cross-validation seeks to minimize the estimated random effects rather than the estimated residuals, can be used to select covariates to include in the model. We show that these methods produce accurate results in a variety of simulated data sets and apply them to two publicly available population pharmacokinetic data sets.

Citing Articles

Assessing the performance of QSP models: biology as the driver for validation.

Singh F, Afzal N, Smithline S, Thalhauser C J Pharmacokinet Pharmacodyn. 2023; 51(5):533-542.

PMID: 37386340 PMC: 11576624. DOI: 10.1007/s10928-023-09871-x.


Cortical excitability signatures for the degree of sleepiness in human.

Chia C, Tang X, Cao Y, Cao H, Zhang W, Wu J Elife. 2021; 10.

PMID: 34313218 PMC: 8373378. DOI: 10.7554/eLife.65099.


Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients.

Wang H, Hu X, Wang T, Cui C, Jiang J, Dong K Front Pharmacol. 2021; 12:645130.

PMID: 33953679 PMC: 8091127. DOI: 10.3389/fphar.2021.645130.


Development and Evaluation of a Prediction Model for Ascertaining Rheumatic Heart Disease Status in Administrative Data.

Bond-Smith D, Seth R, de Klerk N, Nedkoff L, Anderson M, Hung J Clin Epidemiol. 2020; 12:717-730.

PMID: 32753974 PMC: 7358074. DOI: 10.2147/CLEP.S241588.


Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach.

Feldman C, Yoshida K, Xu C, Frits M, Shadick N, Weinblatt M ACR Open Rheumatol. 2019; 1(9):552-559.

PMID: 31777839 PMC: 6857973. DOI: 10.1002/acr2.11068.


References
1.
Mulla H, Nabi F, Nichani S, Lawson G, Firmin R, Upton D . Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2003; 55(1):23-31. PMC: 1884193. DOI: 10.1046/j.1365-2125.2003.01735.x. View

2.
Valodia P, Seymour M, McFadyen M, Miller R, Folb P . Validation of population pharmacokinetic parameters of phenytoin using the parallel Michaelis-Menten and first-order elimination model. Ther Drug Monit. 2000; 22(3):313-9. DOI: 10.1097/00007691-200006000-00013. View

3.
Gal P, Jusko W, Yurchak A, Franklin B . Theophylline disposition in obesity. Clin Pharmacol Ther. 1978; 23(4):438-44. DOI: 10.1002/cpt1978234438. View

4.
Hooker A, Ten Tije A, Carducci M, Weber J, Garrett-Mayer E, Gelderblom H . Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther. 2008; 84(1):111-8. PMC: 3092481. DOI: 10.1038/sj.clpt.6100476. View

5.
Rajagopalan P, Gastonguay M . Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol. 2003; 43(7):698-710. View